Alkeus Pharmaceuticals’ study results from Gildeuretinol shows significant trend in slowing geographic atrophy: Cambridge, Massachusetts Friday, October 25, 2024, 10:00 Hrs [IST ...

Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly ...

Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...

Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...

Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

Age-related macular degeneration (AMD ... GA the "holy grail" in the AMD field because it can lead to vision loss just as severe as wet AMD, but current treatments require monthly injections, have ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...

The therapy, called photobiomodulation or “red light” therapy, can reduce the risk of vision loss and slow progression of the ...

Regenxbio (RGNX) announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients ...

The fight against Age Related Molecular Degeneration Market is seeing a promising boost. According to a recent analysis, the ...